Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Manipal Group Sets Up Stem Cell Arm in Malaysia (Malaysia)

This article was originally published in PharmAsia News

Executive Summary

Stempeutics Research Pvt. Lab recently disclosed plans to open a subsidiary in Malaysia. The startup will be dubbed Stempeutics Research Malaysia Sdn Bhd. Stempeutic's parent company, the India-based Manipal Education and Medical, will invest between $6 million and $10 million in Stempeutics Malaysia over the next three years. Manipal will also use Stempeutics Malaysia as a jumping off point for research and commercialization in Taiwan and Singapore. Manipal has already invested $7 million in Stempeutics for the company's stem cell research program. Stempeutics is currently researching the prospect of using adult stem cells to treat a number of ailments, including myocardial infarction, multiple sclerosis, limb ischemia and cerebral stroke. Adult stem cells come in two forms. The first are autologous stem cells that are harvested from the patient's own bone marrow. Stempeutics is already conducting several clinical trials into the possible benefits of these stem cells. The company is also waiting for approval from the Indian Council of Medical Research to conduct trials with allogenic stem cells. This type of adult stem cell comes from non-related donor cells. Allogenic stem cells have the benefit of being produced on a large scale. Manipal plans to invest $5 million over the next two years to build a cell manufacturing plant in India. (Click here for more

You may also be interested in...

Catchup Capsule: Key APAC Insights You Need To Read

Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.

QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts